


Auvi-Q
epinephrine injection, USP
0.1 mg/0.15 mg/0.3 mg auto-injectors

IS YOUR SCHOOL READY TO RESPOND TO AN ALLERGIC EMERGENCY?



ANAPHYLAXIS CAN HAPPEN ANYWHERE.¹⁻³
AUVI-Q WAS DESIGNED TO BE EASY TO USE.



VOICE INSTRUCTIONS

Step-by-step voice instructions guide users, whether trained or not⁴



AUTO-RETRACTABLE NEEDLE

- Helps prevent needle-related injuries⁵⁻⁷
- The needle is not visible before, during, or after an injection⁴



POCKET-SIZED

About the size of a credit card and thickness of a cell phone

Seek immediate medical treatment after use. Talk to your patients about possible side effects of epinephrine including headache, dizziness, palpitations, sweating, and shakiness.

REMEMBER: Antihistamines are not an appropriate first-line treatment for anaphylaxis. Why? They don't treat all the symptoms, and they don't act quickly. Only epinephrine does that.⁸

Indication

AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.

Important Safety Information

AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after using AUVI-Q. Each AUVI-Q contains a single dose of epinephrine. **AUVI-Q should only be injected into your outer thigh, through clothing if necessary.** If you inject a young child or infant with AUVI-Q, hold their leg firmly in place before and during the injection to prevent injuries.

Please see additional Important Safety Information on the back page, and enclosed full Prescribing Information and Patient Information, or at www.auvi-q.com.

STOCK AUVI-Q TO HELP PREPARE YOUR SCHOOL FOR ALLERGIC EMERGENCIES

1 in 13 CHILDREN

It is estimated that food allergies affect 1 in 13 children, roughly 2 students per classroom.^{9,10*} In a study of anaphylactic reactions in schools, nearly half occurred in the classroom.^{11†}

STOCK EPINEPHRINE

The National Association of School Nurses (NASN) recommends that all schools permitted by state laws maintain undesignated stock epinephrine.¹²



ORDERING AUVI-Q IS EASY.

For pricing, shipping, and ongoing support, find an Authorized Distributor at: auvi-q.com/publicaccess

Have questions?

Email AUVIQPublicAccess@kaleo.com

*Based on a survey of parent-reported outcomes for 38,408 children between 2015-2016.

†Based on a study of 1,992 anaphylaxis events that occurred in schools during 2014-2015.

Important Safety Information (cont'd)

Do not inject AUVI-Q into any other part of your body, such as into veins, buttocks, fingers, toes, hands, or feet. If this occurs, seek immediate medical treatment and make sure to inform the healthcare provider of the location of the accidental injection. Only a healthcare provider should give additional doses of epinephrine if more than two doses are necessary for a single allergic emergency.

Rarely, patients who use AUVI-Q may develop infections at the injection site within a few days of an injection. Some of these infections can be serious. Call your healthcare provider right away if you have any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines you take, especially medicines for asthma. Also tell your healthcare provider about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson's disease, diabetes, heart problems or high blood pressure, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.

Common side effects include fast, irregular or 'pounding' heartbeat, sweating, shakiness, headache, paleness, feelings of over excitement, nervousness, or anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These side effects usually go away quickly, especially if you rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Please see enclosed full Prescribing Information and Patient Information, or at www.auvi-q.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Fleming JT, Clark S, Camargo CA Jr, Rudders SA. Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. *J Allergy Clin Immunol Pract.* 2015;3(1):57-62. 2. Robinson M, Greenhawt M, Stukus DR. Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department. *Ann Allergy Asthma Immunol.* 2017;119(2):164-169. 3. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol.* 2001;107(1):191-193. 4. AUVI-Q [Prescribing Information]. Richmond, VA: kaleo Inc.; <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6180fb40-7fca-4602-b3da-ce62b8cd2470&type=display>. 5. Edwards ES, Edwards ET, Gunn R, Patterson P, North R. Design validation and labeling comprehension study for a new epinephrine autoinjector. *Ann Allergy Asthma Immunol.* 2013;110(3):189-193. 6. Guerlain S, Wang L, Hugine A. Intelliject's novel epinephrine autoinjector: sharps injury prevention validation and comparable analysis with EpiPen and Twinject. *Ann Allergy Asthma Immunol.* 2010;105(6):480-484. 7. Kessler C, Edwards E, Dissinger E, Sye S, Visich T, Grant E. Usability and preference of epinephrine auto-injectors: AUVI-Q and EpiPen Jr. *Ann Allergy Asthma Immunol.* 2019;123(3):256-262. 8. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. *J Allergy Clin Immunol.* 2020;145(4):1082-1123. 9. Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. *Pediatrics.* 2018;142(6):e20181235. 10. Food allergies. Centers for Disease Control and Prevention. Accessed October 2024. <https://www.cdc.gov/healthyschools/foodallergies/index.htm> 11. Hogue SL, Muniz R, Herrem C, Silvia S, White MV. Barriers of administration of epinephrine in schools. *J Sch Health.* 2018;88(5):396-404. 12. Zacharski S, DeSisto M, Pontius D, Sheets J, Richesin C. For your information. Management in the school setting: position statement. *NASN Sch Nurse.* 2013;28(5):263-265.